Cytomegalovirus‐associated chorioretinitis after liver transplantation: case report and review of the literature
暂无分享,去创建一个
O. Bergamin | B. Müllhaupt | N. J. Mueller | H. Hirsch | A. Egli | J. Seebach | N. Mueller | Jorg Dieter Seebach | Adrian Egli | Beat Müllhaupt | Nicolas J Mueller | Hans H. Hirsch | Nicolas J. Mueller
[1] Nina Khanna,et al. Cytomegalovirus and polyomavirus BK posttransplant. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] D. Lilleri,et al. Inconsistent Responses of Cytomegalovirus‐Specific T Cells to pp65 and IE‐1 versus Infected Dendritic Cells in Organ Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] M. Mihatsch,et al. Transient allograft dysfunction from immune reconstitution in a patient with polyoma BK-virus-associated nephropathy. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[4] A. Limaye,et al. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. , 2007, The Journal of infectious diseases.
[5] D. Correa,et al. Acute infection of Toxoplasma gondii and cytomegalovirus reactivation in a pediatric patient receiving liver transplant , 2006, Transplant infectious disease : an official journal of the Transplantation Society.
[6] C. Mengelle,et al. Monitoring human cytomegalovirus (HCMV) in HCMV-seropositive orthotopic liver-transplant recipients by means of quantitative real-time polymerase chain reaction. , 2006, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.
[7] S. Weigand,et al. Effect of antiviral chemoprophylaxis on adverse clinical outcomes associated with cytomegalovirus after liver transplantation. , 2006, Mayo Clinic proceedings.
[8] C. Marroni,et al. Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients. , 2006, Transplantation proceedings.
[9] Valeria Ghisetti,et al. Quantitation of cytomegalovirus DNA by real‐time polymerase chain reaction in peripheral blood specimens of patients with solid organ transplants: Comparison with end‐point PCR and pp65 antigen test , 2006, Journal of medical virology.
[10] A. Limaye,et al. Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral Prophylaxis , 2006, Transplantation.
[11] L. Krogerus,et al. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations , 2006, Transplant infectious disease : an official journal of the Transplantation Society.
[12] S. Shelburne,et al. Immune reconstitution inflammatory syndrome: more answers, more questions. , 2006, The Journal of antimicrobial chemotherapy.
[13] R. Fontana,et al. Efficacy and safety of low‐dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[14] G. Klintmalm,et al. Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome. , 2005, Transplantation.
[15] Chao-Long Chen,et al. The renal‐sparing efficacy of basiliximab in adult living donor liver transplantation , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[16] H. Hirsch. BK virus: opportunity makes a pathogen. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] U. Neumann,et al. Changing impact of cytomegalovirus in liver transplantation – a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis , 2005, Transplant international : official journal of the European Society for Organ Transplantation.
[18] D. Mann,et al. Negative Impact of Human Leukocyte Antigen Matching in the Outcome of Polyomavirus Nephropathy , 2005, Transplantation.
[19] B. Gridelli,et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. , 2005, Transplantation proceedings.
[20] G. Klintmalm,et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] P. Martín-Dávila,et al. Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the optimal cut-off value. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[22] Nina Singh,et al. Who among cytomegalovirus‐seropositive liver transplant recipients is at risk for cytomegalovirus infection? , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[23] D. Mutimer,et al. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus‐seropositive donors , 2005, Transplant infectious disease : an official journal of the Transplantation Society.
[24] M. Pescovitz,et al. Clinical Utility of Cytomegalovirus (CMV) Serology Testing in High‐risk CMV D+/R− Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[25] R. Hetzer,et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1–specific CD8 T cells , 2005, The Journal of experimental medicine.
[26] Nina Singh,et al. Efficacy of Valganciclovir Administered as Preemptive Therapy for Cytomegalovirus Disease in Liver Transplant Recipients: Impact on Viral Load and Late-Onset Cytomegalovirus Disease , 2005, Transplantation.
[27] B. Alexander,et al. Risk Factors for Cytomegalovirus Viremia and Disease Developing after Prophylaxis in High-Risk Solid-Organ Transplant Recipients , 2004, Transplantation.
[28] A. Limaye,et al. Late-Onset Cytomegalovirus Disease in Liver Transplant Recipients Despite Antiviral Prophylaxis1 , 2004, Transplantation.
[29] P. Price,et al. Immune restoration disease after antiretroviral therapy , 2004, AIDS.
[30] M. McCulloch,et al. LIVER TRANSPLANTATION FOR CHILDREN – RED CROSS CHILDREN’S HOSPITAL EXPERIENCE , 2004 .
[31] M. Wagener,et al. T‐helper cell responses in liver transplant recipients: correlation with cytomegalovirus and other major infections , 2004, Transplant infectious disease : an official journal of the Transplantation Society.
[32] S. Fan,et al. Interleukin‐2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: A protocol with early elimination of steroids and reduction of tacrolimus dosage , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[33] M. Battegay,et al. Immune reconstitution in HIV-infected patients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] M. V. Van Natta,et al. Results of a cytomegalovirus (CMV)-specific CD8+/interferon- gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis. , 2004, The Journal of infectious diseases.
[35] M. McCulloch,et al. Liver transplantation for children – the Red Cross Children's Hospital experience , 2004, Pediatric transplantation.
[36] R. Busuttil,et al. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors , 2004, Transplantation.
[37] P. Nyckowski,et al. Cytomegalovirus infection as a common complication following liver transplantation. , 2003, Transplantation proceedings.
[38] S. Singhal,et al. Cytomegalovirus disease following liver transplantation: an analysis of prophylaxis strategies. , 2003, The Journal of infection.
[39] Thomas F. Smith,et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. , 2003, The Journal of infectious diseases.
[40] D. Wolf,et al. Late cytomegalovirus disease following liver transplantation , 2002, Transplant international : official journal of the European Society for Organ Transplantation.
[41] M. L. de la Mata,et al. Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[42] J. S. Daly,et al. Preemptive Strategy for Ganciclovir Administration Against Cytomegalovirus in Liver Transplantation Recipients , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[43] S. Riddell,et al. Association between immune recovery uveitis and a diverse intraocular cytomegalovirus-specific cytotoxic T cell response. , 2002, The Journal of infectious diseases.
[44] M. Lappalainen,et al. Monitoring of Viral Load by Quantitative Plasma PCR during Active Cytomegalovirus Infection of Individual Liver Transplant Patients , 2002, Journal of Clinical Microbiology.
[45] N. Heaton,et al. Cytomegalovirus infection after liver transplantation: viral load as a guide to treating clinical infection , 2002, Transplantation.
[46] P. Price,et al. Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. , 2002, The Journal of infectious diseases.
[47] Thomas F. Smith,et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. , 2002, The Journal of infectious diseases.
[48] K. Batts,et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[49] T. Larson,et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. , 2001, The Journal of infectious diseases.
[50] M. Chen,et al. Association between cytomegalovirus-specific reactivity of T cell subsets and development of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. , 2001, The Journal of infectious diseases.
[51] P. Price,et al. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[52] U. Settmacher,et al. PROSPECTIVE RANDOMIZED TRIAL TO ASSESS THE VALUE OF PREEMPTIVE ORAL THERAPY FOR CMV INFECTION FOLLOWING LIVER TRANSPLANTATION , 2001, Transplantation.
[53] A. Meyerhans,et al. LEVELS OF VIRUS-SPECIFIC CD4 T CELLS CORRELATE WITH CYTOMEGALOVIRUS CONTROL AND PREDICT VIRUS-INDUCED DISEASE AFTER RENAL TRANSPLANTATION1 , 2001, Transplantation.
[54] J. Lerut,et al. USE OF MYCOPHENOLATE MOFETIL AS RESCUE THERAPY AFTER PEDIATRIC LIVER TRANSPLANTATION , 2001, Transplantation.
[55] C. Sabin,et al. Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation. , 2000, The Journal of infectious diseases.
[56] M. Sterneck,et al. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients. , 2000, Transplantation proceedings.
[57] Nina Singh,et al. CYTOMEGALOVIRUS ANTIGENEMIA DIRECTED PRE-EMPTIVE PROPHYLAXIS WITH ORAL VERSUS I.V. GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1: A Randomized, Controlled Trial , 2000, Transplantation.
[58] D. Schoenfeld,et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis , 2000, Transplant infectious disease : an official journal of the Transplantation Society.
[59] P. Francioli,et al. Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: relationship between compliance with the guidelines and prevention of CMV morbidity , 2000, Transplant infectious disease : an official journal of the Transplantation Society.
[60] W. Bechstein,et al. Infectious complications after orthotopic liver transplantation with different immunosuppressive induction regimens. , 2000, Transplantation proceedings.
[61] R. Rubin,et al. Prevention dof recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir , 2000 .
[62] V. Balakrishnan,et al. Quantitation of peripheral blood cytomegalovirus DNA for monitoring recurrent cytomegalovirus retinitis in pediatric solid organ transplant recipients , 2000, Pediatric transplantation.
[63] J. Andersson,et al. High‐dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients , 1999, Transplant infectious disease : an official journal of the Transplantation Society.
[64] R. Rubin,et al. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir. , 1999, Transplant infectious disease : an official journal of the Transplantation Society.
[65] W. Freeman,et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. , 1999, The Journal of infectious diseases.
[66] R. Rubin,et al. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. , 1998, Transplantation.
[67] R. Wiesner,et al. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. , 1998, Transplantation.
[68] D. Paterson,et al. Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. , 1998, Transplantation.
[69] U. Neumann,et al. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation. , 1998, Clinical transplantation.
[70] R. Wiesner,et al. Clinical significance of viral load in the diagnosis of cytomegalovirus disease after liver transplantation. , 1998, Transplantation.
[71] J. Gavaldà,et al. Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[72] P. McCluskey,et al. Ocular complications of heart, lung, and liver transplantation , 1998, The British journal of ophthalmology.
[73] W. Freeman,et al. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. , 1998, Archives of ophthalmology.
[74] J. Contreras,et al. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. , 1998, Transplantation.
[75] R. Busuttil,et al. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors. , 1997, Transplantation.
[76] M. Pescovitz,et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients , 1997, The Lancet.
[77] J. Reyes,et al. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[78] R. Busuttil,et al. Randomized comparison of ganciclovir plus intravenous immune globulin (IVIG) with IVIG alone for prevention of primary cytomegalovirus disease in children receiving liver transplants. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[79] J. Gavaldà,et al. Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV‐seropositive liver transplant recipients , 1997, Transplant international : official journal of the European Society for Organ Transplantation.
[80] J. Griffith,et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. , 1997, Clinical transplantation.
[81] R. Dalton,et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy , 1997, The Lancet.
[82] M. Emond,et al. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation. , 1997, Clinical transplantation.
[83] R. Wiesner,et al. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. , 1997, Transplantation.
[84] G. Papanicolaou,et al. Infectious ocular complications in orthotopic liver transplant patients. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[85] E. Elias,et al. Patterns of viremia in liver transplant recipients with symptomatic cytomegalovirus infection. , 1997, Transplantation.
[86] D. Snydman,et al. Primary cytomegalovirus infection in liver transplant recipients: comparison of infections transmitted via donor organs and via transfusions. Boston Center for Liver Transplantation CMVIG Study Group. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[87] W. Bechstein,et al. The importance of late infections for the long‐term outcome after liver transplantation , 1996, Transplant international : official journal of the European Society for Organ Transplantation.
[88] D. Snydman,et al. Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients , 1996 .
[89] K. St. George,et al. Time to detection of cytomegalovirus (CMV) DNA in blood leukocytes is a predictor for the development of CMV disease in CMV-seronegative recipients of allografts from CMV-seropositive donors following liver transplantation. , 1996, The Journal of infectious diseases.
[90] R. Vaughan,et al. Antibody removal and subsequent transplantation of a highly sensitised paediatric renal patient , 1996, Transplant international : official journal of the European Society for Organ Transplantation.
[91] R. Wiesner,et al. Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients. , 1996, The Journal of infectious diseases.
[92] R. Busuttil,et al. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. , 1995, Transplantation.
[93] J. Neuberger,et al. Quantitation of cytomegalovirus in the blood of liver transplant recipients. , 1995, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[94] R. Busuttil,et al. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients , 1995, The Lancet.
[95] R. Wiesner,et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. , 1995, The Journal of infectious diseases.
[96] B. Meyers,et al. High-dose acyclovir and intravenous immune globulin reduce the incidence of CMV disease after liver transplantation , 1995, Transplant international : official journal of the European Society for Organ Transplantation.
[97] A. Niveleau,et al. Monitoring levels of human cytomegalovirus DNA in blood after liver transplantation , 1995, Journal of clinical microbiology.
[98] W. Bechstein,et al. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. , 1995, Transplantation.
[99] T. Peters,et al. Cold Ischemia And Outcome In 17,937 Cadaveric Kidney Transplants , 1995, Transplantation.
[100] K. St. George,et al. Diagnosis of cytomegalovirus infections by shell vial assay and conventional cell culture during antiviral prophylaxis , 1994, Journal of clinical microbiology.
[101] T. Starzl,et al. A PROSPECTIVE RANDOMIZED TRIAL COMPARING SEQUENTIAL GANCICLOVIR‐HIGH DOSE ACYCLOVIR TO HIGH DOSE ACYCLOVIR FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE IN ADULT LIVER TRANSPLANT RECIPIENTS , 1994, Transplantation.
[102] M. Samore,et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. , 1994, The Journal of infectious diseases.
[103] R. Wiesner,et al. Detection of cytomegalovirus DNA in sera of liver transplant recipients , 1994, Journal of clinical microbiology.
[104] Nina Singh,et al. High-Dose Acyclovir Compared with Short-Course Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Liver Transplant Recipients , 1994, Annals of Internal Medicine.
[105] S. Hammer,et al. Cytomegalovirus Immune Globulin Prophylaxis in Liver Transplantation , 1993, Annals of Internal Medicine.
[106] G. Cleghorn,et al. Cytomegalovirus infection after liver transplantation in children , 1993, Journal of gastroenterology and hepatology.
[107] J. Preiksaitis,et al. Cytomegalovirus disease in liver transplant recipients: impact of acyclovir prophylaxis. , 1993, Transplantation proceedings.
[108] R. Chaisson,et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. , 1992, The Journal of infectious diseases.
[109] C. Payá,et al. Low predictive value of polymerase chain reaction for diagnosis of cytomegalovirus disease in liver transplant recipients , 1992, Journal of clinical microbiology.
[110] F. Luks,et al. Infectious complications of pediatric liver transplantation. , 1991, Journal of pediatric surgery.
[111] E. Roberts,et al. Cytomegalovirus infections in pediatric liver transplantation. , 1990, American journal of diseases of children.
[112] Meyers Jd,et al. Prophylaxis of cytomegalovirus infection. , 1990, Seminars in hematology.
[113] R. Calne,et al. Viral and toxoplasma gondii infections in children after liver transplantation. , 1990, Journal of clinical pathology.
[114] R. Stratta,et al. Clinical patterns of cytomegalovirus disease after liver transplantation. , 1989, Archives of surgery.
[115] R. Wiesner,et al. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. , 1989, The Journal of infectious diseases.
[116] J. Ludwig,et al. Rapid shell vial culture and tissue histology compared with serology for the rapid diagnosis of cytomegalovirus infection in liver transplantation. , 1989, Mayo Clinic proceedings.
[117] W. V. van Son,et al. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood , 1988, Journal of clinical microbiology.
[118] S. Hammer,et al. GANCICLOVIR THERAPY OF SEVERE CYTOMEGALOVIRUS INFECTIONS IN SOLID‐ORGAN TRANSPLANT RECIPIENTS , 1988, Transplantation.
[119] T. Starzl,et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. , 1988, The Journal of infectious diseases.
[120] H. Balfour,et al. Cytomegalovirus infection of the liver in transplant recipients. , 1987, Journal of clinical gastroenterology.
[121] H. Balfour,et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. , 1987, JAMA.
[122] T. Starzl,et al. Decreased incidence of viral infections in liver transplant recipients , 2005, Digestive Diseases and Sciences.
[123] M. Makuuchi,et al. Risk factors of cytomegalovirus infection after living donor liver transplantation. , 2005, Hepato-gastroenterology.
[124] D. Snydman,et al. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study. , 2001, Transplantation proceedings.
[125] T. Drewniak,et al. Diagnosis and monitoring of cytomegalovirus infection after liver transplantation in children. , 1996, Annals of transplantation.
[126] D. Snydman,et al. Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. , 1996, Transplantation.
[127] M. Chobanian,et al. Changing spectrum of pediatric renal transplantation. , 1994, Transplantation proceedings.
[128] T. F. Smith,et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. , 1993, Journal of hepatology.